Table 3. Anti-SARS-CoV-2 S Titer after the Second Doses of ChAdOx1 nCOV-19 according to Adverse Reactions.
| Adverse events | After 1st dose | p-value | After 2nd dose | p value | ||
|---|---|---|---|---|---|---|
| Yes | No | Adverse events | Adverse events | |||
| Pain or tenderness | 646.0 (381.0–1070.0) | 407.0 (231.0–821.5) | 0.019 | 642.0 (375.0–1117.7) | 597.5 (355.0–925.2) | 0.165 |
| Redness | 793.0 (415.7–1083.2) | 609.0 (357.0–1000.0) | 0.151 | 800.0 (516.7–1094.5) | 616.0 (359.7–1000.0) | 0.290 |
| Swelling | 619.0 (409.5–889.5) | 630.0 (359.0–1050.0) | 0.768 | 773.0 (519.0–1123.0) | 616.0 (358.5–983.0) | 0.177 |
| Itching | 628.5 (379.7–983.2) | 623.0 (360.2–1037.5) | 0.831 | 534.0 (367.0–832.0) | 630.0 (363.5–1025.0) | 0.337 |
| Fever | 575.5 (354.0–953.5) | 656.5 (377.2–1043.0) | 0.251 | 569.0 (269.0–826.5) | 648.0 (370.0–1022.0) | 0.421 |
| Nausea or vomiting | 623.0 (478.0–976.0) | 624.5 (358.7–1005.5) | 0.755 | 556.0 (422.2–782.2) | 647.0 (364.7–1029.0) | 0.512 |
| Diarrhea | 582.0 (299.0–907.0) | 630.0 (366.5–1060.0) | 0.575 | 299.0 (243.0–589.5) | 630.0 (371.0–1022.0) | 0.065 |
| Headache | 638.0 (371.5–1011.0) | 606.0 (354.0–964.0) | 0.586 | 616.0 (368.5–978.5) | 630.0 (361.0–1011.0) | 0.910 |
| Myalgia or fatigue | 619.0 (367.0–966.0) | 630.0 (360.5–1221.5) | 0.687 | 1050.0 (646.0–1770.2) | 960.5 (606.0–1534.0) | 0.543 |
SARS-CoV-2, severe respiratory syndrome-coronavirus-2.
Anti-SARS-CoV-2 S titer (U/mL) are shown as median and interquartile range (Q1–Q3). Anti-SARS-CoV-2 titer was assessed using serum collected 2 months after the second dose of ChAdOx1 nCOV-19.